Idelalisib-Induced Pneumonitis in Chronic Lymphocytic Leukemia
Sasikanth N Ravi, Irene W Choi, Eva K Ngapgue, Amanda G Stroiney, Clive J Miranda
TL;DR
This paper discusses a case of lung inflammation caused by a drug used to treat chronic lymphocytic leukemia and emphasizes the need for early diagnosis and personalized treatment.
Contribution
The paper presents a case report of idelalisib-induced pneumonitis and highlights the importance of early diagnosis and tailored treatment.
Findings
Idelalisib, a PI3Kδ inhibitor, is effective in treating relapsed chronic lymphocytic leukemia.
Idelalisib can cause pneumonitis, a serious side effect requiring early diagnosis and individualized treatment for better outcomes.
Abstract
Idelalisib, a phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, effectively treats relapsed chronic lymphocytic leukemia (CLL). While this targeted approach offers a therapeutic edge, particularly in B-cell malignancies, it is associated with complications such as pneumonitis. This report details idelalisib-induced pneumonitis, highlighting the importance of early diagnosis and tailored treatment in achieving a favorable patient outcome.
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Click any figure to enlarge with its caption.
Figure 1
Figure 2
Figure 3Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsChronic Lymphocytic Leukemia Research · Chronic Myeloid Leukemia Treatments · PI3K/AKT/mTOR signaling in cancer